A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer

Annals of Oncology

Volumn 17, Issue 4, 2006, Pages 663-667

  Schmittel, Alexander ^a   von Weikersthal, L Fischer ^c   Sebastian, M ^d   Martus, P ^a   Schulze, K ^b   Hortig, P ^b   Reeb, M ^e   Thiel, E ^a   Keilholz, U ^a  

^a Oncology and Transfusion Medicine ^*  (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c St Marien Hospital   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e Westpfalz Clinic   (Germany)

Author keywords

Carboplatin; Etoposide; Extensive disease; Irinotecan; Phase II; SCLC

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IRINOTECAN; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; ENDOCARDITIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; THROMBOCYTOPENIA; VOMITING;

EID: 33645327676     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj137     Document Type: Article

References (18)

1. Ruth BJ, Johnson DH, Einhorn LH et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10: 282-291.
2. Ueoka H, Kiura K, Tabata M et al. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/ cisplatin and etoposid (PVP) versus sequential administration of VAV-PVP for the treatment of patients with small cell lung carcinoma: Results of long term follow-up. Cancer 1998; 83: 283-290.
3. Von Pawel J, Schiller JH, Shepherd FA et al. Topotecan versus cyclophosphamide, doxorubicine, and vincristine for the treatment of recurrent small cell lung cancer. J Clin Oncol 1999; 17: 658-667.
4. Noda K, Nishiwaki Y, Kawahara M et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small lung cancer. N Engl J Med 2002; 346: 85-91.
5. Hirose T, Horichi N, Ohmori T et al. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer. Lung Cancer 2003; 40: 333-338.
6. Naka N, Kawahara M, Okishio K et al. Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer. Lung Cancer 2002; 37: 319-323.
7. Hanna NH, Einhorn L, Sandler A et al. Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients with previously untreated, extensive-stage small cell lung cancer. Proc ASCO 2005, LBA 7004.
8. Skarlos DV, Samantas E, Kosmidis P et al. Randomized comparison of etoposid-cisplatin vs. etoposid-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994; 5: 601-607.
9. Lassen U, Kristjansen PE, Osterlind K et al. Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. Ann Oncol 1996; 7: 365-371.
10. Schmittel A, Schulze K, Hütter G et al. Phase I dose escalation study of carboplatin to a fixed dose of Irinotecan as first-line treatment of small cell lung cancer. Onkologie 2004; 27: 280-284.
11. Fukuda M, Oka M, Soda H et al. Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. Clin Cancer Res 1999; 5: 3963-3969.
12. Jones SF, Burris HA 3rd, Hainsworth JD et al. Phase I trial of irinotecan plus carboplatin in two dose schedules. Oncology 2003; 5 (Suppl 5): 36-40.
13. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-1756.
14. Jelliffe RW. Creatinine clearance: Bedside estimate. Ann Intern Med 1973; 79: 604-605.
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
16. Wolf M, Havemann K, Holle R et al. Cisplatin/etoposide versus ifosfamide/ etoposide combination chemotherapy in small-cell lung cancer: A multicenter German randomized trial. J Clin Oncol 1987; 5: 1880-1889.
17. Kehrer DF, Sparreboom A, Verweij J et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 2001; 7: 1136-1141.
18. Schmittel A, Jahnke K, Thiel E et al. Neomycin as secondary prophylaxis for irinotecan-induced diarrhea. Ann Oncol 2004; 15: 1296.